1
|
Denis C, Saulière A, Galandrin S, Sénard JM, Galés C. Probing heterotrimeric G protein activation: applications to biased ligands. Curr Pharm Des 2012; 18:128-44. [PMID: 22229559 DOI: 10.2174/138161212799040466] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2011] [Accepted: 11/09/2011] [Indexed: 12/17/2022]
Abstract
Cell surface G protein-coupled receptors (GPCRs) drive numerous signaling pathways involved in the regulation of a broad range of physiologic processes. Today, they represent the largest target for modern drugs development with potential application in all clinical fields. Recently, the concept of "ligand-directed trafficking" has led to a conceptual revolution in pharmacological theory, thus opening new avenues for drug discovery. Accordingly, GPCRs do not function as simple on-off switch but rather as filters capable of selecting the activation of specific signals and thus generating texture responses to ligands, a phenomenon often referred to as ligand-biased signaling. Also, one challenging task today remains optimization of pharmacological assays with increased sensitivity so to better appreciate the inherent texture of ligands. However, considering that a single receptor has pleiotropic signaling properties and that each signal can crosstalk at different levels, biased activity remains thus difficult to evaluate. One strategy to overcome these limitations would be examining the initial steps following receptor activation. Even, if some G protein independent functions have been recently described, heterotrimeric G protein activation remains a general hallmark for all GPCRs families and the first cellular event subsequent to agonist binding to the receptor. Herein, we review the different methodologies classically used or recently developed to monitor G protein activation and discussed them in the context of G protein biased-ligands.
Collapse
Affiliation(s)
- Colette Denis
- Institut des Maladies Métaboliques et Cardiovasculaires, Université Toulouse III Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, France.
| | | | | | | | | |
Collapse
|
2
|
Hossain M, Ahmed M, Bhuiyan MA, Ishiguro M, Nakamura T, Ozaki M, Nagatomo T. Mutation of important amino acid residue of Asp104Lys in human beta(1)-adrenergic receptor triggers functional and constitutive inactivation. Biol Pharm Bull 2008; 31:1517-22. [PMID: 18670082 DOI: 10.1248/bpb.31.1517] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Based on our previous molecular modeling and radioligand binding study, we have demonstrated that aspartic acid of 104 in transmembrane helix (TMH) II of beta(1)-adrenergic receptor (beta(1)-AR) is important for functional characteristics of these receptors. We have also showed that mutation of negatively charged aspartic acid to neutral charged alanine exhibited constitutive activity of beta(1)-AR. However, the mutation of negatively charged aspartic acid to positively charged lysine is still remained to be examined, which is very important to know for fully understanding the characteristics of beta(1)-AR. At the present study, we mutated aspartic acid to lysine (Asp104Lys) residue in human beta(1)-AR. This resultant mutant (Asp104Lys) markedly reduced the binding affinity of isoproterenol and (-)-epinephrine. On the other hand, antagonist binding with this mutant was similar to the wild type receptor. Isoproterenol at its saturation concentrations produced lower amount of intracellular cyclic adenosine-3',5' cyclic monophosphate (cAMP) in HEK-293 cells expressing Asp104Lys mutant receptor as compared to cells expressing wild type receptor. Moreover, cAMP accumulation of Asp104Lys mutant was unchanged in the presence or absence of isoproterenol. Therefore, it has been demonstrated that Asp104Lys mutation in the human beta(1)-AR differentially affects the binding of antagonist and exhibits a functional uncoupling of G-protein-coupled receptors. Thus, we may suggest that mutation of negatively charged aspartic acid to positively charged lysine as well as neutral charged alanine may help to understand the mechanism of the activation or inactivation of beta(1)-AR by its conformational changes and this finding would be helpful for clarifying the functional responses mediated by beta(1)-AR.
Collapse
Affiliation(s)
- Murad Hossain
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
| | | | | | | | | | | | | |
Collapse
|
3
|
Roth CB, Hanson MA, Stevens RC. Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure. J Mol Biol 2007; 376:1305-19. [PMID: 18222471 DOI: 10.1016/j.jmb.2007.12.028] [Citation(s) in RCA: 112] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2007] [Revised: 12/07/2007] [Accepted: 12/12/2007] [Indexed: 11/26/2022]
Abstract
G protein-coupled receptor (GPCR) instability represents one of the most profound obstacles in the structural study of GPCRs that bind diffusible ligands. The introduction of targeted mutations at nonconserved residues that lie proximal to helix interfaces has the potential to enhance the fold stability of the receptor helix bundle while maintaining wild-type receptor function. To test this hypothesis, we studied the effect of amino acid substitutions at Glu122(3.41) in the well-studied beta(2)-adrenergic receptor (beta(2)AR), which was predicted from sequence conservation to lie at a position equivalent to a tryptophan residue in rhodopsin at the 3,4,5 helix interface among transmembrane (TM) domains 3, 4, and 5. Replacement of Glu122(3.41) with bulky hydrophobic residues, such as tryptophan, tyrosine, and phenylalanine, increases the yield of functionally folded beta(2)AR by as much as 5-fold. Receptor stability in detergent solution was studied by isothermal denaturation, and it was found that the E122W and E122Y mutations enhanced the beta(2)AR thermal half-life by 9.3- and 6.7-fold, respectively, at 37 degrees C. The beta(1)AR was also stabilized by the introduction of tryptophan at Glu147(3.41), and the effect on protein behavior was similar to the rescue of the unstable wild-type receptor by the antagonist propranolol. Molecular modeling of the E122W and E122Y mutants revealed that the tryptophan ring edge and tyrosine hydroxyl are positioned proximal to the helical break in TM5 introduced by the conserved Pro211(5.50) and may stabilize the helix by interacting favorably with the unpaired carbonyl oxygen of Val206(5.45). Conformational flexibility of TM5 is likely to be a general property of class A GPCRs; therefore, engineering of the TM4-TM3-TM5 interface at the 3.41 position may provide a general strategy for the stabilization of other receptors.
Collapse
Affiliation(s)
- Christopher B Roth
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
4
|
Kobilka BK, Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 2007; 28:397-406. [PMID: 17629961 DOI: 10.1016/j.tips.2007.06.003] [Citation(s) in RCA: 518] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2007] [Revised: 05/23/2007] [Accepted: 06/26/2007] [Indexed: 10/23/2022]
Abstract
G-protein-coupled receptors (GPCRs) are remarkably versatile signaling molecules. Members of this large family of membrane proteins respond to structurally diverse ligands and mediate most transmembrane signal transduction in response to hormones and neurotransmitters, and in response to the senses of sight, smell and taste. Individual GPCRs can signal through several G-protein subtypes and through G-protein-independent pathways, often in a ligand-specific manner. This functional plasticity can be attributed to structural flexibility of GPCRs and the ability of ligands to induce or to stabilize ligand-specific conformations. Here, we review what has been learned about the dynamic nature of the structure and mechanism of GPCR activation, primarily focusing on spectroscopic studies of purified human beta2 adrenergic receptor.
Collapse
Affiliation(s)
- Brian K Kobilka
- Stanford University School of Medicine, 157 Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.
| | | |
Collapse
|
5
|
Abstract
G protein-coupled receptors (GPCRs) mediate responses to hormones and neurotransmitters, as well as the senses of sight, smell, and taste. These remarkably versatile signaling molecules respond to structurally diverse ligands. Many GPCRs couple to multiple G protein subtypes, and several have been shown to activate G protein-independent signaling pathways. Drugs acting on GPCRs exhibit efficacy profiles that may differ for different signaling cascades. The functional plasticity exhibited by GPCRs can be attributed to structural flexibility and the existence of multiple ligand-specific conformational states. This chapter will review our current understanding of the mechanism by which agonists bind and activate GPCRs.
Collapse
Affiliation(s)
- Xavier Deupi
- Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305, USA
| | | |
Collapse
|
6
|
Ahmed M, Muntasir HA, Hossain M, Ishiguro M, Komiyama T, Muramatsu I, Kurose H, Nagatomo T. Beta-blockers show inverse agonism to a novel constitutively active mutant of beta1-adrenoceptor. J Pharmacol Sci 2006; 102:167-72. [PMID: 17031074 DOI: 10.1254/jphs.fp0060640] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
We obtained a new mutant of the beta(1)-adrenergic receptor (beta(1)-AR) by point mutations that can constitutively activate beta(1)-AR. Aspartate104 of the beta(1)-AR in the 2nd transmembrane was replaced with alanine. The beta(1)-AR mutant expressed in human embryonic kidney (HEK)-293 cells displayed high level of constitutive activity with respect to wild-type (P<0.05), which could be partially inhibited by some beta-blockers. The constitutive activity of the mutant was confirmed by the finding that the enhanced activity is dependent on the level of receptor expression. The results of this study might have interesting implications for future studies aiming at elucidating the activation process of the beta(1)-AR as well as the mechanism of action of beta-blockers.
Collapse
Affiliation(s)
- Maruf Ahmed
- Pharmacy Department, University of Rajshahi, Bangladesh
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
G protein-coupled receptor (GPCR)-Galpha fusion proteins were first characterized more than 10 years ago as a strategy for studying receptor-G protein signaling. A large number of studies have used this approach to characterize receptor coupling to members of the Gs, Gi, and Gq families of Galpha subunits, but this strategy has not been widely used to study Galpha12 and Galpha13. As described in the article by Zhang et al. in this issue of Molecular Pharmacology (p. 1433) characterization of the signaling properties of thromboxane A2 receptor (TPalpha) -Galpha12 and -Galpha13 fusion constructs demonstrates the applicability of this strategy to members of this unique family of Galpha subunits, and how this strategy can be used to resolve otherwise difficult problems of receptor pharmacology associated with these proteins. The general strategy of making receptor-Galpha fusion constructs has wide applicability to a number of research problems, but there are perhaps also "hidden messages" in how different receptor-Galpha subunit fusion pairs behave.
Collapse
Affiliation(s)
- John D Hildebrandt
- Department of Cell and Molecular Pharmacology, Medical University of South Carolina, 173 Ashley Ave., 303BSB, Charleston, SC 29425, USA.
| |
Collapse
|
8
|
Zhang YQ, Limbird LE. Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem Soc Trans 2005; 32:856-60. [PMID: 15494033 DOI: 10.1042/bst0320856] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Complexes of alpha(2A)-ARs (alpha(2A)-adrenergic receptors) and MORs (mu-opioid receptors), probably hetero-oligomers, were detected by co-immunoisolation after extraction from HEK-293 cells (human embryonic kidney 293 cells). Functional communication between these receptors is revealed by alpha(2A)-AR activation of a pertussis toxin-insensitive G(i)alpha subunit (termed as G(i)1) when fused with the MOR and evaluated in membranes from pertussis toxin-treated cells. However, the alpha(2A)-AR does not require transactivation through MOR, since quantitatively indistinguishable results were observed in cells co-expressing alpha(2A)-AR and a fusion protein of G(i)1 with the first transmembrane span of MOR (myc-MOR-TM1). Functional cross-talk among these alpha(2A)-AR-MOR complexes does not occur for internalization profiles; incubation with adrenaline (epinephrine) leads to endocytosis of alpha(2A)-AR but not MOR, while incubation with DAMGO ([D-Ala,NMe-Phe,Gly-ol]enkephalin) leads to endocytosis of MOR but not alpha(2A)-AR in cells co-expressing both the receptors. Hence, alpha(2A)-AR and MOR hetero-oligomers, although they occur, do not have an obligatory functional influence on one another in the paradigms studied.
Collapse
Affiliation(s)
- Y Q Zhang
- Department of Pharmacology and Center for Molecular Neuroscience, Vanderbilt University Medical Center, 2200 Pierce Ave., 464A RRB, Nashville, TN 37232-6600, USA
| | | |
Collapse
|
9
|
Ott D, Neldner Y, Cèbe R, Dodevski I, Plückthun A. Engineering and functional immobilization of opioid receptors. Protein Eng Des Sel 2005; 18:153-60. [PMID: 15790572 DOI: 10.1093/protein/gzi012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Opioid receptors, like many G protein-coupled receptors (GPCRs), are notoriously unstable in detergents. We have now developed a more stable variant of the mu-opioid receptor (MOR) and also a method for the immobilization of solubilized, functional opioid receptors on a solid phase (magnetic beads). Starting with the intrinsically more stable kappa-opioid receptor (KOR), we optimized the conditions (i.e. detergents and stabilizing ligands) for receptor extraction from lipid bilayers of HEK293T cells to obtain maximal amounts of functional, immobilized receptor. After immobilization, the ligand binding profile remains the same as observed for the membrane-embedded receptor. For the immobilized wild-type mu-opioid receptor, however, no conditions were found under which ligand binding capacity was retained. To solve this problem, we engineered the receptor chimera KKM where the N-terminus and the first transmembrane helix (TM1) of wild-type MOR is exchanged for the homologous receptor parts of the wild-type KOR. This hybrid receptor behaves exactly as the wild-type MOR in functional assays. Interestingly, the modified MOR is expressed at six times higher levels than wild-type MOR and is similarly stable as wild-type KOR after immobilization. Hence the immobilized MOR, represented by the chimera KKM, is now also amenable for biophysical characterization. These results are encouraging for future stability engineering of GPCRs.
Collapse
Affiliation(s)
- David Ott
- Biochemisches Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | | | | | | | | |
Collapse
|
10
|
Ott D, Frischknecht R, Plückthun A. Construction and characterization of a kappa opioid receptor devoid of all free cysteines. Protein Eng Des Sel 2004; 17:37-48. [PMID: 14985536 DOI: 10.1093/protein/gzh004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
We have constructed an optimized mutant of the kappa opioid receptor (KOR), which is devoid of its 10 free cysteines. It was necessary to test different amino acid replacements at various positions and we used a structural model and homology with other receptor family members as a guide. This mutant binds ligands and couples to the cognate G-proteins in a very similar fashion to wild-type KOR. The addition of the antagonist naloxone during cell growth greatly enhances heterogeneous expression of the mutant in mammalian cells, such that amounts similar to wild-type could be produced. We showed by fluorescence microscopy that naloxone stabilizes the mutant in the plasma membrane. This mutant, which now permits the insertion of single cysteines, was designed for use in spectroscopic studies of ligand-induced receptor conformational changes as well as to simplify folding studies.
Collapse
Affiliation(s)
- David Ott
- Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | | | | |
Collapse
|
11
|
Rezmann-Vitti LA, Louis SNS, Nero TL, Jackman GP, Iakovidis D, Machida CA, Louis WJ. Agonist binding and activation of the rat beta(1)-adrenergic receptor: role of Trp(134(3.28)), Ser(190(4.57)) and Tyr(356(7.43)). Biochem Pharmacol 2004; 68:675-88. [PMID: 15276075 DOI: 10.1016/j.bcp.2004.04.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2004] [Accepted: 04/27/2004] [Indexed: 11/21/2022]
Abstract
We investigated the role of Trp(134(3.28)), Ser(190(4.57)) and Tyr(356(7.43)) in agonist binding to, and activation of, the rat beta(1)-adrenergic receptor by comparing pK(i)s and functional responses of W134A, S190A and Y356F mutant receptors to wild type, all stably expressed in CHO cells. All three mutations significantly (P < 0.05) reduced adenylyl cyclase intrinsic activity (IA) compared to wild type in response to stimulation with both (-)-isoprenaline (53-88%) and (-)-RO363 (46-61%), and there was no significant correlation either between IA or pD(2) and pK(i) (P > 0.4), suggesting that changes in pK(i) were not sufficient to explain the fall in adenylyl cyclase activity. The most pronounced reduction in affinity (126-fold, P < 0.01) was displayed by xamoterol for the Y356F mutation, suggesting that xamoterol is able to directly interact with Tyr(356(7.43)). For the other agonists, the change in pK(i) values for the mutant receptors ranged from a 20-fold decrease to a 2-fold increase compared to the wild type. In a three-dimensional model of the rat beta(1)-adrenergic receptor, Trp(134(3.28)) and Tyr(356(7.43)) form part of a hydrophobic binding pocket involving residues in transmembrane helices 1, 2, 3 and 7. Our results suggest that Trp(134(3.28)) and Tyr(356(7.43)), together with Trp(353(7.40)), are able to interact via pi-pi interactions to stabilize the extracellular ends of transmembrane helices 3 and 7. Ser(190(4.57)) appears to be involved in a hydrogen bonding network, which maintains the spatial relationship between transmembrane helices 3 and 4. These interhelical interactions suggest that the three mutated residues stabilize the active receptor state by maintaining the proper packing of their respective transmembrane helix within the helix bundle, facilitating the appropriate movement and rotation of the transmembrane regions during the activation process.
Collapse
Affiliation(s)
- Linda A Rezmann-Vitti
- Department of Medicine, Clinical Pharmacology and Therapeutics Unit, The University of Melbourne, Austin Health, Heidelberg 3084, Vic., Australia
| | | | | | | | | | | | | |
Collapse
|
12
|
Zeng FY, McLean AJ, Milligan G, Lerner M, Chalmers DT, Behan DP. Ligand Specific Up-Regulation of aRenilla reniformisLuciferase-Tagged, Structurally Unstable Muscarinic M3Chimeric G Protein-Coupled Receptor. Mol Pharmacol 2003; 64:1474-84. [PMID: 14645678 DOI: 10.1124/mol.64.6.1474] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The rat muscarinic acetylcholine receptor subtype 3 was modified by swapping the third intracellular loop with the corresponding region of a constitutively active mutant human beta2-adrenergic receptor and attaching Renilla reniformis luciferase to its C terminus. The chimeric fusion receptor displayed constitutive Gq- and Gs-coupled activity as demonstrated in nuclear factor of activated T cell and cAMP response element reporter gene assays. The chimeric receptor displayed a pharmacological binding profile comparable with that of the wild-type receptor for agonists, antagonists, and inverse agonists but showed a large decrease in expression in both human embryonic kidney 293 and COS-7 cells. Long-term treatment of cells expressing the chimeric receptor with agonists, antagonists, and inverse agonists resulted in a concentration-dependent up-regulation in the steady-state levels that was not observed for the wild-type receptor. The EC50 of neutral antagonists and inverse agonists was significantly correlated to their binding affinities at the wild-type receptor, whereas agonists demonstrated greater EC50 values for the chimeric receptor. To validate the approach as a means of discovering novel receptor modulators, a cell-based, high-throughput screening assay was developed and used to screen a small molecule compound collection against the chimeric fusion receptor. Several novel hits were identified and confirmed by ligand binding assay and functional assays using the wild-type rat muscarinic acetylcholine receptor subtype 3.
Collapse
Affiliation(s)
- Fu-Yue Zeng
- Arena Pharmaceuticals Inc. 6166 Nancy Ridge Drive, San Diego, CA 92121, USA.
| | | | | | | | | | | |
Collapse
|
13
|
Feng GJ, Kellett E, Scorer CA, Wilde J, White JH, Milligan G. Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation. J Biol Chem 2003; 278:33400-7. [PMID: 12810704 DOI: 10.1074/jbc.m305866200] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Analysis of interactions between the C-terminal tail of the MOP-1 and MOP-1A variants of the human mu-opioid receptor with proteins derived from a human brain cDNA library resulted in identification of the actin and intermediate filament-binding protein periplakin. Mapping of this interaction indicated that the predicted fourth intracellular loop/helix VIII of the receptor interacts with the C-terminal rod and linker region of periplakin. Periplakin is widely expressed in the central nervous system of both man and rat and demonstrated an overlapping but not identical distribution with mu-opioid (MOP) receptors. Co-expression of periplakin with MOP-1 or a MOP-1-eYFP fusion construct in HEK293 cells did not interfere with agonist-mediated internalization of the receptor. When co-expressed with a MOP-1-Gi1 alpha fusion protein periplakin significantly reduced the capacity of the agonist to stimulate binding of 35S-labeled guanosine 5'-3-O-(thio)triphosphate ([35S]GTP gamma S) to the receptor-associated G protein. By contrast, periplakin did not interfere with agonist-stimulation of [35S]GTP gamma S binding to either an alpha 2A-adrenoreceptor-Gi1 alpha fusion protein or a beta2-adrenoreceptor-Gs alpha fusion protein, indicating its selectivity of function. This represents the first example of an opioid receptor-interacting protein that functions to disrupt agonist-mediated G protein activation.
Collapse
MESH Headings
- Actins/chemistry
- Amino Acid Sequence
- Biotin/pharmacology
- Brain/metabolism
- Cell Line
- Cell Membrane/metabolism
- Central Nervous System/metabolism
- Cytoskeletal Proteins/chemistry
- DNA/metabolism
- DNA, Complementary/metabolism
- GTP-Binding Proteins/metabolism
- Gene Library
- Glutathione Transferase/metabolism
- Guanosine 5'-O-(3-Thiotriphosphate)/metabolism
- Histidine/chemistry
- Humans
- Immunoblotting
- Ligands
- Microscopy, Confocal
- Microscopy, Fluorescence
- Molecular Sequence Data
- Plakins
- Protein Binding
- Protein Isoforms
- Protein Structure, Tertiary
- RNA, Messenger/metabolism
- Receptors, Opioid, mu/chemistry
- Receptors, Opioid, mu/metabolism
- Recombinant Fusion Proteins/metabolism
- Sequence Homology, Amino Acid
- Tissue Distribution
- Transfection
- Two-Hybrid System Techniques
Collapse
Affiliation(s)
- Giu-Jie Feng
- Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom
| | | | | | | | | | | |
Collapse
|
14
|
Abstract
High-content assays rely on the imaging of cellular events. They can be used to monitor the activation of G-protein-coupled receptors (or other receptors), their internalization into the cell, or alterations in their amount. In addition, multiplexed assays can provide further information about the characteristics of the receptor. Recent improvements in throughput using high-content screening platforms means that such assays are now an integral element of functional analysis in the drug discovery process.
Collapse
Affiliation(s)
- Graeme Milligan
- Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK G12 8QQ.
| |
Collapse
|
15
|
Abstract
Ligand regulation of the binding of [35S]GTPgammaS is one of the most widely used methods to measure receptor activation of heterotrimeric G proteins. However, until recently this method was largely restricted to receptors that interact with members of the family of pertussis-toxin-sensitive G proteins. Here, the reasons for this restriction are discussed and recent approaches that have extended the utility of this method such that it is now suitable for analysis of the activation of any heterotrimeric G protein are reviewed.
Collapse
Affiliation(s)
- Graeme Milligan
- Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Scotland, UK.
| |
Collapse
|